Opus Genetics (IRD) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $4.05, -1.22% vs the prior close of $4.10.
- Volume 2.90M shares, 1.0x its 50-day average.
- New SEC filings: 8-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
IRD dips 1.2% to $4.05, a 1-month low, 4 down days in a row. Closed at $4.05, -1.22% vs the prior close of $4.10. Day range $3.98–$4.28, opened at $4.15.
IRD daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — IRD dips 1.2% to $4.05, a 1-month low, 4 down days in a row
- Closed at $4.05, -1.22% vs the prior close of $4.10. Day range $3.98–$4.28, opened at $4.15.
- Volume was 2.90M shares, 1.0x its 50-day average of 2.82M.
- Price is -9.7% vs its 50-day average ($4.48) and -1.0% vs its 200-day average ($4.09).
- 52-week range $1.70–$7.07; today's close sits at 44% of that range, 42.7% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 14, 2026 — IRD slides 3.3% to $4.10, a 1-month low, 3 down days in a row
- Closed at $4.10, -3.30% vs the prior close of $4.24. Day range $4.08–$4.40, opened at $4.40.
- Volume was 1.20M shares, 0.4x its 50-day average of 2.81M — lighter than usual.
- Price is -8.4% vs its 50-day average ($4.48) and +0.5% vs its 200-day average ($4.08).
- 52-week range $1.70–$7.07; today's close sits at 45% of that range, 42.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — IRD slides 8.6% to $4.24, a 1-month low
- Closed at $4.24, -8.62% vs the prior close of $4.64. Day range $4.23–$4.77, opened at $4.76.
- Volume was 1.29M shares, 0.5x its 50-day average of 2.81M — lighter than usual.
- Price is -5.1% vs its 50-day average ($4.47) and +4.1% vs its 200-day average ($4.07).
- 52-week range $1.70–$7.07; today's close sits at 47% of that range, 40.0% below the 52-week high.
Oct 12, 2026 — IRD ends flat (-0.2%) to $4.64
- Closed at $4.64, -0.22% vs the prior close of $4.65. Day range $4.60–$4.88, opened at $4.63.
- Volume was 1.62M shares, 0.6x its 50-day average of 2.80M — lighter than usual.
- Price is +4.1% vs its 50-day average ($4.46) and +14.3% vs its 200-day average ($4.06).
- 52-week range $1.70–$7.07; today's close sits at 55% of that range, 34.4% below the 52-week high.
Oct 9, 2026 — IRD jumps 4.3% to $4.65, 3 up days in a row
- Closed at $4.65, +4.26% vs the prior close of $4.46. Day range $4.45–$4.74, opened at $4.46.
- Volume was 1.26M shares, 0.4x its 50-day average of 2.80M — lighter than usual.
- Price is +4.7% vs its 50-day average ($4.44) and +14.9% vs its 200-day average ($4.05).
- 52-week range $1.70–$7.07; today's close sits at 55% of that range, 34.2% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — IRD rises 1.1% to $4.46
- Closed at $4.46, +1.13% vs the prior close of $4.41. Day range $4.25–$4.48, opened at $4.41.
- Volume was 1.35M shares, 0.5x its 50-day average of 2.79M — lighter than usual.
- Price is +0.8% vs its 50-day average ($4.42) and +10.6% vs its 200-day average ($4.03).
- 52-week range $1.70–$7.07; today's close sits at 51% of that range, 36.9% below the 52-week high.
Oct 7, 2026 — IRD rises 0.7% to $4.41
- Closed at $4.41, +0.68% vs the prior close of $4.38. Day range $4.25–$4.66, opened at $4.35.
- Volume was 1.84M shares, 0.7x its 50-day average of 2.76M.
- Price is +0.1% vs its 50-day average ($4.40) and +9.7% vs its 200-day average ($4.02).
- 52-week range $1.70–$7.07; today's close sits at 50% of that range, 37.6% below the 52-week high.
Oct 6, 2026 — IRD ends flat (+0.0%) to $4.38
- Closed at $4.38, +0.00% vs the prior close of $4.38. Day range $4.19–$4.48, opened at $4.47.
- Volume was 2.53M shares, 0.9x its 50-day average of 2.72M.
- Price is -0.1% vs its 50-day average ($4.38) and +9.2% vs its 200-day average ($4.01).
- 52-week range $1.70–$7.07; today's close sits at 50% of that range, 38.0% below the 52-week high.
Oct 5, 2026 — IRD slides 4.4% to $4.38
- Closed at $4.38, -4.37% vs the prior close of $4.58. Day range $4.34–$4.64, opened at $4.57.
- Volume was 2.53M shares, 0.9x its 50-day average of 2.70M.
- Price is +0.4% vs its 50-day average ($4.36) and +9.6% vs its 200-day average ($4.00).
- 52-week range $1.70–$7.07; today's close sits at 50% of that range, 38.0% below the 52-week high.
Oct 2, 2026 — IRD rises 1.6% to $4.58
- Closed at $4.58, +1.55% vs the prior close of $4.51. Day range $4.45–$4.67, opened at $4.56.
- Volume was 1.79M shares, 0.7x its 50-day average of 2.69M.
- Price is +5.6% vs its 50-day average ($4.34) and +14.9% vs its 200-day average ($3.99).
- 52-week range $1.70–$7.07; today's close sits at 54% of that range, 35.2% below the 52-week high.
IRD latest news & SEC filings
Every SEC filing by or about IRD in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Foundation Fighting Blindness Retinal Degeneration Fund & Foundation Fighting Blindness, Inc. sold 556,000 shares at $4.96 (≈$2.76M) on Sep 30, 2026; now holds 3,236,171
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gagnon Robert E. sold 28,000 shares at $4.54 (≈$127.12K) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form CORRESP — Company letter to the SEC
Company letter to the SEC
Aug 12, 2026 · Form UPLOAD — SEC staff letter to the company
SEC staff letter to the company
Aug 7, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade IRD
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 10, 2026, Feb 19, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.79% (largest 8.6%).
- Liquidity: about 2.01M shares (≈$8.13M) trade per day on average.
- 52-week position: $4.05 vs a range of $1.70–$7.07 (44% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 2 open-market buys, 19 sales; latest: Robert E. Gagnon sold 28,000 shares on Sep 3, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Sep 11, 2026; 8-K Sep 9, 2026.
- Share count: 83.20M shares outstanding (Aug 3, 2026), +38.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
IRD market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 4.15 | 4.28 | 3.98 | 4.05 | 2.90M |
| Oct 14, 2026 | 4.40 | 4.40 | 4.08 | 4.10 | 1.20M |
| Oct 13, 2026 | 4.76 | 4.77 | 4.23 | 4.24 | 1.29M |
| Oct 12, 2026 | 4.63 | 4.88 | 4.60 | 4.64 | 1.62M |
| Oct 9, 2026 | 4.46 | 4.74 | 4.45 | 4.65 | 1.26M |
| Oct 8, 2026 | 4.41 | 4.48 | 4.25 | 4.46 | 1.35M |
| Oct 7, 2026 | 4.35 | 4.66 | 4.25 | 4.41 | 1.84M |
| Oct 6, 2026 | 4.47 | 4.48 | 4.19 | 4.38 | 2.53M |
| Oct 5, 2026 | 4.57 | 4.64 | 4.34 | 4.38 | 2.53M |
| Oct 2, 2026 | 4.56 | 4.67 | 4.45 | 4.58 | 1.79M |
| Oct 1, 2026 | 4.89 | 4.91 | 4.51 | 4.51 | 1.87M |
| Sep 30, 2026 | 4.96 | 5.32 | 4.83 | 4.84 | 2.46M |
| Sep 29, 2026 | 5.07 | 5.15 | 4.80 | 4.96 | 1.53M |
| Sep 28, 2026 | 4.75 | 5.14 | 4.63 | 5.05 | 1.16M |
| Sep 25, 2026 | 4.89 | 4.93 | 4.70 | 4.76 | 1.24M |
| Sep 24, 2026 | 4.76 | 4.96 | 4.60 | 4.87 | 1.83M |
| Sep 23, 2026 | 5.14 | 5.16 | 4.65 | 4.83 | 3.06M |
| Sep 22, 2026 | 5.20 | 5.30 | 5.04 | 5.16 | 1.17M |
| Sep 21, 2026 | 5.17 | 5.55 | 5.17 | 5.22 | 1.98M |
| Sep 18, 2026 | 5.29 | 5.34 | 5.11 | 5.18 | 5.54M |
About Opus Genetics
Opus Genetics (IRD) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in DURHAM, NC. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1228627.
IRD board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Sean Ainsworth | Director | Apr 22, 2026 |
| Jean Bennett | Director | Apr 22, 2026 |
| Susan Benton | Director | Apr 22, 2026 |
| Fighting Blindness Retinal Degeneration Fund Foundation | See Remarks | May 20, 2026 |
| Fighting Blindness, Inc. Foundation | See Remarks | May 20, 2026 |
| Cam Gallagher | Director | Sep 8, 2026 |
| Adrienne L Graves | Director | Apr 22, 2026 |
| James S J Manuso | Director | Apr 22, 2026 |
| George Magrath | Chief Executive Officer | Sep 11, 2026 |
| Richard J Rodgers | Director | Apr 22, 2026 |
| Benjamin R Yerxa | President | Jul 27, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert E. Gagnon | Chief Financial Officer | Sep 8, 2026 |
| Ashwath Jayagopal | Chief Scientific & Dev. Ofc. | Apr 27, 2026 |
| George Magrath | Chief Executive Officer | Sep 11, 2026 |
| Joseph K Schachle | Chief Operating Officer | Jul 27, 2026 |
| Benjamin R Yerxa | President | Jul 27, 2026 |
| Rabourn Amy Zaremba | Head of Fin. Quality Assurance | Apr 27, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | Robert E. Gagnon | Sale | 28,000 | $4.54 |
| Jul 23, 2026 | Benjamin R Yerxa | Sale | 7,429 | $2.97 |
| Jul 23, 2026 | Robert E. Gagnon | Sale | 7,783 | $2.95 |
| Jul 23, 2026 | George Magrath | Sale | 9,475 | $2.95 |
| Jul 23, 2026 | Joseph K Schachle | Sale | 4,644 | $2.94 |
| May 18, 2026 | Fighting Blindness Retinal Degeneration Fund Foundation | Sale | 1,700,000 | $4.35 |
| May 18, 2026 | Fighting Blindness, Inc. Foundation | Sale | 1,700,000 | $4.35 |
| Apr 23, 2026 | Benjamin R Yerxa | Sale | 7,470 | $5.24 |
| Apr 23, 2026 | Joseph K Schachle | Sale | 4,697 | $5.22 |
| Apr 23, 2026 | George Magrath | Sale | 9,511 | $5.22 |
| Apr 23, 2026 | Robert E. Gagnon | Sale | 7,842 | $5.18 |
| Apr 23, 2026 | Ashwath Jayagopal | Sale | 7,542 | $5.19 |
| Apr 23, 2026 | Rabourn Amy Zaremba | Sale | 1,641 | $5.20 |
| Mar 16, 2026 | Rabourn Amy Zaremba | Sale | 2,816 | $5.25 |
| Mar 16, 2026 | Joseph K Schachle | Sale | 3,719 | $5.25 |
IRD financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $14.20M | $-49.59M | -0.80 | $-35.25M |
| Dec 31, 2024 | $10.99M | $-57.53M | -2.15 | $-25.58M |
| Dec 31, 2023 | $19.05M | $-9.99M | -0.46 | $-1.11M |
| Dec 31, 2022 | $39.85M | $17.89M | 0.87 | $14.31M |
| Dec 31, 2021 | $589.00K | $-56.69M | -3.82 | $-19.37M |
Latest balance sheet: total assets $92.97M, total liabilities $105.95M, cash $88.81M (as of Jun 30, 2026).
IRD earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $3.72 |
| May 12, 2026 | 8-K Item 2.02 (results) | $5.18 |
| Mar 10, 2026 | 8-K Item 2.02 (results) | $4.85 |
| Feb 19, 2026 | 8-K Item 2.02 (results) | $3.57 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.92 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $1.10 |
| May 15, 2025 | 8-K Item 2.02 (results) | $0.95 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $0.98 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $1.15 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $1.14 |
| Oct 22, 2024 | 8-K Item 2.02 (results) | $1.33 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)AMD (AMD)Apple (AAPL)Tesla (TSLA)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on IRD
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.